Niagen Bioscience (NASDAQ:NAGE) Posts Earnings Results

Niagen Bioscience (NASDAQ:NAGE) announced its earnings results on Wednesday. The company reported $0.05 EPS for the quarter, FiscalAI reports. The business had revenue of $33.84 million during the quarter. Niagen Bioscience had a net margin of 16.38% and a return on equity of 24.13%.

Niagen Bioscience Trading Up 1.4%

Shares of NASDAQ NAGE opened at $4.94 on Thursday. The company has a market capitalization of $394.24 million, a P/E ratio of 20.58 and a beta of 2.11. Niagen Bioscience has a 12 month low of $4.72 and a 12 month high of $14.69. The stock has a 50 day moving average of $5.80 and a 200-day moving average of $7.19.

Hedge Funds Weigh In On Niagen Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. New York State Teachers Retirement System bought a new position in shares of Niagen Bioscience in the fourth quarter valued at about $30,000. Financial Consulate Inc. acquired a new position in Niagen Bioscience in the 3rd quarter valued at about $33,000. State of Alaska Department of Revenue bought a new position in Niagen Bioscience in the 3rd quarter valued at about $44,000. Ameritas Investment Partners Inc. acquired a new stake in Niagen Bioscience during the third quarter worth approximately $45,000. Finally, North Star Investment Management Corp. bought a new stake in shares of Niagen Bioscience during the third quarter worth approximately $47,000. 15.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on NAGE shares. Canaccord Genuity Group cut their price target on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.33.

Niagen Bioscience News Roundup

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Q4 and FY2025 results beat consensus: Q4 net sales rose to $33.8M (Tru Niagen® $27.5M, +21% YoY) and FY2025 net sales were $129.4M (+30% YoY). Gross margin expanded to 64.1% and fiscal‑year net income roughly doubled to $17.4M. These fundamentals drove enthusiasm. Business Wire: FY2025 Results
• Positive Sentiment: Earnings and EPS beats for the quarter: reported Q4 EPS topped estimates (Zacks/other outlets note beats vs consensus), supporting the stock reaction. Zacks: Tops Estimates
• Positive Sentiment: Market reaction: multiple outlets report a strong after‑hours rally following the results and remarks on 2026 growth outlook, reflecting investor enthusiasm. Benzinga: Rallies After Hours
• Neutral Sentiment: Company emphasized “double‑digit” sales growth for FY2026 in its guidance and commentary — a positive directional signal for growth investors, but the exact EPS guidance was not highlighted in headlines. Yahoo: Valuation After New 2026 Guidance
• Negative Sentiment: FY2026 revenue guidance range ($142.4M–$148.8M) was below the Street consensus (~$153.3M), which could temper upside despite growth wording — a likely reason for mixed intraday reactions. Yahoo: Guidance vs Consensus
• Negative Sentiment: Q4 net income declined versus the prior-year quarter ($4.1M vs $7.2M), which investors may view as a short‑term margin/cost timing flag despite full‑year profitability gains. Business Wire: Q4 Details

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.